Abstracts tagged "autoimmune diseases"

Abstract Number: 0356 • ACR Convergence 2025
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Stephen Poos¹, Hoang Nguyen², Samuel Greenberg³, Marcus Lee², Heidi Roppelt¹ and Asha Patnaik², ¹Stony Brook Southampton Hospital, Southampton, NY, ²Stony Brook University Hospital, Stony Brook, NY, ³Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
Background/Purpose: Osteoporosis is under screened in men. The United States Preventive Services Task Force (USPSTF) does not publish guidelines for osteoporosis screening in men. Other…
Abstract Number: 0263 • ACR Convergence 2025
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Michelle Benjamin¹, Mattia Wruble Clark², Shamik Bhattacharyya³, Audra Horomanski¹ and Kristin Galetta⁴, ¹Stanford University, Palo Alto, CA, ²Mass General Brigham, Somerville, MA, ³Brigham and Women's Hospital, Malden, MA, ⁴Stanford Medical Center, Palo Alto
Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can…
Abstract Number: 0201 • ACR Convergence 2025
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Ana Victoria Esteban Vázquez¹, Martina Steiner², Cristina Vergara², Elisabet Castañeda Estévez³, Maria Beatriz Paredes Romero⁴, Isabel De La Camara-Fernandez¹, Laura Trives¹, Tatiana Cobo¹, Patricia Richi⁵, Maria liz Romero⁵, Marta De San Segundo³, Antonio Sanchis³, Carolina Marín⁶, Maria Teresa Navio Marco⁷ and Santiago Muñoz¹, ¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Infanta Sofía University Hospital, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁷Infanta Leonor Universitary Hospital, Madrid, Spain
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) receiving Janus Kinase Inhibitors (JAKi) are at increased risk of herpes zoster reactivation. The adjuvanted recombinant zoster vaccine…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Matthew Martin¹, Erik Wilker¹, Diana Gikunju¹, Usha Narayanan¹, Unnati Pandya¹, Vijetha Prakash¹, Ashley Edwards¹, Sameer Kawatkar¹, Tenghui Chen¹, Ragunath Chandran¹, Sai Sunder¹, Sumathi Biradar¹, Joerg Distler², Alexandra Joseph¹, Stephanos Ioannidis¹ and Bhavatarini Vangamudi¹, ¹Exo Therapeutics, Cambridge, MA, ²Exo Therapeutics, Düsseldorf, Germany
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
John Tesser¹, Joshua June², Pendleton Wickersham³, Jane Box⁴, Guillermo Valenzuela⁵, Angela Crowley⁶, Nikila Kumar⁷, Norman Gaylis⁸, Gordan Lam⁹, David Ridley¹⁰, Gineth Paola Pinto-Patarroyo¹¹ and David Chernoff¹², ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Great Lakes Center of Rheumatology, Lansing, MI, ³Arthritis Associates PA, San Antonio, TX, ⁴DJL Clinical Research, PLLC, Charlotte, NC, ⁵Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁶Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁷Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, ⁸Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁹Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Fairfax, VA, ¹²SetPoint Medical, Sausalito, CA
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Chunli Mei¹, Xin Guan¹, Bin Wu², Mengjiao Li¹, Xiaojing Liu¹, Xi Chen¹, You Song¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Xing Zhao³, Xuanfan Zhong³, Shengjie Xue³, Wuzhong Shen³, Ying Tan³, Guojian Yu³, Guiyun Tu³, Hanyang Chen³, Amy Sun³, Xiaoqiang Yan³, Anbing Huang¹, Rong Du¹ and Qiubai Li¹, ¹Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, ³ITabMed Ltd. Changchun, Shanghai, China
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
Abstract Number: L19 • ACR Convergence 2024
Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials
Alexei Grom¹, Uwe Ullman², Adnan Mahmood³, Josefin Blomkvist³, Brian Jamieson⁴ and Fabrizio De Benedetti⁵, ¹Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ²Sobi, Basel, Switzerland, ³Sobi, Stockholm, Sweden, ⁴Sobi, Inc., Morrisville, NC, ⁵Bambino Gesu Children's Hospital, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
Abstract Number: 0010 • ACR Convergence 2024
Precision Editing of Cyclophilin a to Engineer Cyclosporine- and Voclosporin- Resistant Human CAR-T Cells
Holly Wobma¹, Francesca Alvarez-Calderon², Jiayi Dong², Alexandre Albanese², Kayleigh Omdahl², Rene Bermea³, Gillian Selig⁴, Marlana Winschel², Elisa Rojas Palato², Katherine Michaelis¹, Xianliang Rui², Bruce Blazar⁵, Susan Prockop², Victor Tkachev³, Ulrike Gerdemann² and Leslie Kean², ¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA, ³Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ⁴Harvard College, Boston, MA, ⁵Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN
Background/Purpose: With exponential demand for chimeric antigen receptor (CAR) therapies for autoimmune disease, allogeneic options will be essential. Advantages include use of healthy donor cells,…
Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Christina Donath¹, Sara Kahlown¹, Ryan Soares², Kamal Gautam², Mariam Saleh³, Banki Katalin⁴ and Andras Perl⁵, ¹SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ²SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, ³SUNY Upstate University Hospital, Syracuse, NY, ⁴SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ⁵SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
Abstract Number: 0257 • ACR Convergence 2024
High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action
Jaspreet Bhatti¹, Kyu-In Lee¹, Arushika Yedla¹, Julia Ash¹, James Miceli¹, Kirk Sperber¹ and Amy Wasserman², ¹Westchester Medical Center, Valhalla, NY, ²Westchester Medical Center, Valhalla
Background/Purpose: Strongyloides Stercoralis is a human intestinal nematode widely found in tropical and subtropical regions that frequently causes chronic and asymptomatic infection (Table 1). Immunosuppression in a host…
Abstract Number: 0331 • ACR Convergence 2024
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Gianluca sambataro², iazsmin Ventura³, Francisca Bozan⁴, Eduardo Dourado⁵, Sara Faghihi-Kashani⁶, Aravinthan Loganathan⁷, Daphne Rivero Gallegos⁸, Akira Yoshida⁹, Giovanni Zanframundo¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Andrew Mammen¹⁸, Neil McHugh¹⁹, Frederick Miller²⁰, Carlomaurizio Montecucco²¹, Antonella Notarnicola²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo A. Scire²⁶, Albert Gil-Vila²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²University of Catania, Catania, Italy, ³Section of Rheumatology, University of Chicago, Chicago, IL, ⁴Hospital Clinico Universidad de Chile, Santiago, Chile, ⁵Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸INER, Ciudad de México, Mexico State, Mexico, ⁹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹⁰Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸NIH, Bethesda, MD, ¹⁹University of Bath, Bath, United Kingdom, ²⁰NIH, NIEHS, Chapel Hill, NC, ²¹IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²²Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Universitat Autònoma of Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].